IP Library Granted Patent US 11,684,681
Granted Patent B2
US 11,684,681 · App. 17/379,402 · Granted Jun 27, 2023

Method of detecting eosinophil degranulation in the respiratory tract

Inventors: Leonard F. Pease (Salt Lake City, UT); Hedieh Saffari (Salt Lake City, UT); Gerald J. Gleich (Salt Lake City, UT); Kristin M. Leiferman (Salt Lake City, UT); Kathryn A. Peterson (Salt Lake City, UT); Russell Morris Condie (Salt Lake City, UT)
Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
A61K51/0491A61K51/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,684,681
App. No.
17/379,402
Granted
Jun 27, 2023
Kind
B2
Abstract

Disclosed are methods of detecting eosinophil degranulation in the respiratory tract of subjects. Also, disclosed are methods of producing medical images of the respiratory tract of subjects. The method can include administering radiolabeled heparin to the respiratory tract of subjects, wherein the radiolabeled heparin binds to one or more eosinophil granule protein in the mucosal tissue of the respiratory tract.

Claims (16)

1. A method of detecting eosinophil degranulation in a respiratory tract passage of a subject, the method comprising:

administering radiolabeled heparin to the respiratory tract passage of the subject, wherein the radiolabeled heparin binds to one or more eosinophil granule proteins in the mucosal tissue of the respiratory tract passage; and

detecting the radiolabeled heparin in the mucosal tissue of the respiratory tract passage by one of single-photon emission computed tomography (SPECT), positron emission tomography (PET), conventional or computed tomography (CT), magnetic resonance imaging (MRI), or combinations thereof, hereby wherein detecting the radiolabeled heparin in the mucosal tissue is indicative of eosinophil degranulation in the respiratory tract passage of the subject.

2. The method of claim 1 , wherein the radiolabeled heparin binds to the one or more eosinophil granule proteins to form a radiolabeled heparin eosinophil granule protein complex, and wherein detecting the radiolabeled heparin comprises detecting the radiolabeled heparin eosinophil granule protein complex by one of single-photon emission computed tomography (SPECT), positron emission tomography (PET), conventional or computed tomography (CT), magnetic resonance imaging (MRI), or combinations thereof.

3. The method of claim 1 , wherein the one or more eosinophil granule proteins comprise one or more of major basic protein 1 (MBP-1), major basic protein 2 (MBP-2), eosinophil derived neurotoxin (EDN), eosinophil cationic protein (ECP), and eosinophil peroxidase (EPO).

4. The method of claim 1 , wherein the radiolabel is 99m Tc.

5. The method of claim 1 , wherein the respiratory tract passage is selected from the group consisting of a nose, a sinus, a lung, and a bronchus of the subject.

6. The method of claim 1 , wherein the respiratory tract passage is a paranasal sinus cavity.

7. A method of producing a medical image of a respiratory tract passage of a subject, the method comprising:

administering radiolabeled heparin to the respiratory tract passage of the subject, wherein the radiolabeled heparin binds to one or more eosinophil granule proteins in the mucosal tissue of the respiratory tract passage; and

detecting the radiolabeled heparin by one of single-photon emission computed tomography (SPECT), positron emission tomography (PET), conventional or computed tomography (CT), magnetic resonance imaging (MRI), or combinations thereof, thereby producing a medical image of the respiratory tract passage of the subject.

8. The method of claim 7 , wherein the radiolabeled heparin binds to the one or more eosinophil granule proteins to form a radiolabeled heparin eosinophil granule protein complex and wherein detecting the radiolabeled heparin comprises detecting the radiolabeled heparin eosinophil granule protein complex by one of single-photon emission computed tomography (SPECT), positron emission tomography (PET), conventional or computed tomography (CT), magnetic resonance imaging (MRI), or combinations thereof.

9. The method of claim 7 , wherein the one or more eosinophil granule proteins comprise one or more of major basic protein 1 (MBP-1), major basic protein 2 (MBP-2), eosinophil derived neurotoxin (EDN), eosinophil cationic protein (ECP), and eosinophil peroxidase (EPO).

10. The method of claim 7 , wherein the radiolabel is 99m Tc.

11. The method of claim 7 , wherein the respiratory tract passage is selected from the group consisting of a nose, a sinus, a lung, and a bronchus of the subject.

12. The method of claim 7 , wherein the respiratory tract passage is a paranasal sinus cavity.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2021
From: SAFFARI, HEDIEH; GLEICH, GERALD J.; LEIFERMAN, KRISTIN M.; PETERSON, KATHRYN A.; CONDIE, RUSSELL MORRIS
To: UNIVERSITY OF UTAH
Reel/Frame 057293/0472 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2021
From: PEASE, LEONARD F.; SAFFARI, HEDIEH; GLEICH, GERALD J.; LEIFERMAN, KRISTIN M.; PETERSON, KATHRYN A.; CONDIE, RUSSELL MORRIS
To: UNIVERSITY OF UTAH
Reel/Frame 056949/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2021
From: UNIVERSITY OF UTAH
To: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Reel/Frame 056949/0970 →
Continuity (6)
Continuation 16502328 · Jul 3, 2019
Continuation 15719827 · Sep 29, 2017
Continuation 14402070
Provisional Application 61786909 · Mar 15, 2013
Provisional Application 61688650 · May 18, 2012
Related Publication 20220054662A1 · Feb 24, 2022